---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126787"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:26:11.227993+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k

## Summary
- Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.
- Gross margin improved to 46.0% from 45.1% YoY; operating loss narrowed to $0.3M from $0.4M.
- Adjusted EBITDA loss of $75k, near breakeven versus $0.4M loss a year ago.
- Cash balance $1.0M at quarter end; secured $0.9M net proceeds from Streeterville financing.
- Launched +PlusHLTH supplement line (CLARITY, PEACE, RESHAPE) and new pet chews.

## SEC filing metadata
- accession: 0000950170-24-126787
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000095017024126787/0000950170-24-126787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000095017024126787/cvsi-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126787
- JSON: https://secwatch.observer/filing/0000950170-24-126787.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.